Login / Signup

Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma.

Zahra GoudarziRahil Sadat ShahtaheriZhila NajafpourHaleh HamedifarHamidreza Ebrahimi
Published in: Cost effectiveness and resource allocation : C/E (2024)
DRd triplet therapy compared to KRd is a cost-effective regimen for RRMM under Iran willingness-to-pay threshold.
Keyphrases
  • multiple myeloma
  • low dose
  • high dose
  • health insurance
  • stem cells
  • energy transfer
  • mesenchymal stem cells
  • acute lymphoblastic leukemia
  • cell therapy
  • bone marrow
  • stem cell transplantation
  • quantum dots